Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
T. Smirnova (Moscow, Russian Federation), E. Antonov (Moscow, Russian Federation), S. Andreevskaya (Moscow, Russian Federation), S. Bogorodski (Moscow, Russian Federation), L. Chernousova (Moscow, Russian Federation), V. Popov (Moscow, Russian Federation). Bioresorbable polymer structures - promising carriers for prolonged forms of anti-tuberculosis drugs. 459

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of imatinib loaded-antiCD44 coated gold nanoparticles: a possible new therapeutic approach to BOS Source: International Congress 2019 – Lung transplantation: from basic science to clinical outcomes Year: 2019 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Polyacrylate nanoparticles: toxicity or new nanomedicine? Source: Eur Respir J 2010; 36: 218-221 Year: 2010 Inhaled solid lipid nanoparticles as a new tool for drug delivery in the lung Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 The challenges of severe pneumonia: new pathogens, new drugs and new formulations Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Nebulised lipid–polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells Source: ERJ Open Res, 5 (2) 00161-2018; 10.1183/23120541.00161-2018 Year: 2019 Characterisation of clinical phenotypes is mandatory for the development of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011